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Objective: Schizophrenia is associated with atopy and increased inﬂammatory markers. We report a population-
based longitudinal study of the associations between childhood atopic disorders, subsequent serum inﬂammatory
markers, interleukin 6 (IL-6) and C-reactive protein (CRP), and the risk of psychotic experiences (PEs).
Method: PEswere assessed at age 13 years (n = 6785). Presence of clinician-diagnosed atopic disorders (asthma
and eczema)was determined fromparent-completedquestionnaires at age 10 years (n = 7814). Serum IL-6 and
CRP were measured at age 9 years (n = 5076). Logistic regression examined the association between (1) atopy
and PEs, (2) inﬂammatorymarkers and PEs, and (3)mediating effects of inﬂammatorymarkers on the atopy–PEs
association. Linear regression examined the association between atopy and inﬂammatory markers. Age, gender,
social class, ethnicity and body mass index were included as potential confounders.
Results: At age 10 years, about 14% of the sample was reported to have asthma, 12% eczema, and 7% both asth-
ma and eczema. Compared with children with no atopy, risk of PEs at age 13 years was increased for all of
these groups; adjusted odds ratios (95% CI) were, respectively, 1.39 (1.10–1.77), 1.33 (1.04–1.69), and 1.44
(1.06–1.94). Atopy was associated with increased serum IL-6 and CRP; however, this did not mediate associa-
tion between atopy and PEs. Inﬂammatory markers were not associated with later PEs.
Conclusion: Childhood atopic disorders increase the risk of psychotic experiences in adolescence. Follow-up
of these individuals will be useful to determine the effect of atopy and inﬂammation on different trajectories
of early-life PEs.
© 2013 The Authors. Published by Elsevier B.V.
1. Introduction
Several lines of evidence link adult psychotic illness with infection
and abnormalities in various components of the immune system. In-
creased prevalence of antibodies to Toxoplasma gondiihas been reported
in schizophrenia (Torrey et al., 2012). Maternal infection (Buka et al.,
2001a; Brown et al., 2004a, 2005; Mortensen et al., 2007; Brown and
Derkits, 2010; Mortensen et al., 2010; Khandaker et al., 2012b), raised
serum inﬂammatory markers during pregnancy (Buka et al., 2001b;
Brown et al., 2004b), and childhood infection (Rantakallio et al., 1997;
Dalman et al., 2008; Khandaker et al., 2012a) have been reported to be as-
sociated with the increased risk of schizophrenia in adult life. Studies of
individualswithﬁrst episode psychosis or acute psychotic relapse suggest
an increase in proinﬂammatory cytokines in serum (Miller et al., 2011),
a marker of activation of the innate immune response (Weizman and
Bessler, 1999). A recent meta-analysis has reported increased serum
C-reactive protein (CRP) in schizophrenia (Miller et al., 2013). However,
longitudinal studies of circulating markers of inﬂammation in childhood
and subsequent risk of psychotic outcomes are lacking.
Increased autoantibodies against various brain regions and ion chan-
nels have been reported in adult psychotic illness (Rothermundt et al.,
2001; Zandi et al., 2011), a marker of activation of the adaptive immune
response. Epidemiological studies have also reported increased preva-
lence of autoimmune conditions in schizophrenia, and family members
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of patients with schizophrenia (Eaton et al., 2006; Chen et al., 2012).
Adaptive immune response elicited by non-infectious antigens underlies
atopic disorders such as asthma, atopic dermatitis, urticaria and allergic
rhinitis (Janeway et al., 2001). Therefore, it has been suggested that
examination of possible links between immune responses and the devel-
opment of schizophrenia should include atopic conditions as possible
contributing factors (Rottem and Shoenfeld, 2003). The evidence base
on this subject is growing. So far, two cross-sectional studies have report-
ed increased prevalence of asthma in schizophrenia (Chen et al., 2009;
Weber et al., 2009). Recently, a large population-based longitudinal
study has reported increased risk of adult schizophrenia in individuals
with atopic disorders (asthma, atopic dermatitis, urticaria and allergic
rhinitis) earlier in life (Pedersen et al., 2012). Effects of inﬂammatory re-
sponse on the developing brain have been proposed as one mechanism
that may underlie this association (Pedersen et al., 2012); also, other
epidemiological observations of associations between early life infection
and adult schizophrenia (Brown and Derkits, 2010; Khandaker et al.,
2012a, 2012b). However, empirical data on this topic involving human
subjects is limited (Buka et al., 2001b; Brown et al., 2004b).
Population-based birth cohort studies have reported increased
risk of adult psychotic illness among individuals reporting psychotic
experiences (PEs) during childhood and adolescence (Poulton et al.,
2000; Zammit et al., 2013). Early-life PEs also have been linked with
a number of risk factors for schizophrenia (Horwood et al., 2008;
Thomas et al., 2009; Zammit et al., 2009). Therefore, it has been sug-
gested that studies of early-life PEs may be helpful to elucidate the
pathophysiology of adult psychotic disorders (Kelleher and Cannon,
2011; Murray and Jones, 2012).
Using data from the population-based Avon Longitudinal Study
of Parents and Children (ALSPAC) birth cohort, we report associations
between early-life atopic disorders, serum inﬂammatory markers
(interleukin 6 or IL-6 and CRP) at age 9 years, and the risk of PEs at
age 13 years. We predicted that atopic disorders will be associated
with both increased levels of inﬂammatory markers and the risk of
PEs. We also predicted that inﬂammatory markers will be associated
with the risk of PEs, and ﬁnally, that they will mediate the association
between atopic disorders and PEs. Fig. 1 illustrates the timing of data
collection and the hypotheses tested.
2. Method
2.1. Sample
The ALSPAC birth cohort is based on all pregnant women residing
in the county of Avon, a geographically deﬁned region in the southwest
of England, with expected dates of delivery between April 1991 and
December 1992 (www.alspac.bris.ac.uk). The initial ALSPAC cohort
consisted of 14,062 live births and 13,988 infants still alive at 12 months
(Boyd et al., 2013; Fraser et al., 2013). Avon included both urban and
rural areas, and the populationwas broadly representative of all children
in theUK. The parents completed regular postal questionnaires about all
aspects of their child's health and development since birth. Since the
age of 7 years the children attended an annual assessment clinic during
which they participated in a range of face-to-face interviews and physi-
cal tests. The current study is based on 6784 individuals who completed
the Psychosis-like Symptoms interview (PLIKSi) at age 13 years.
Ethical approval for the study was obtained from ALSPAC Ethics
and Law Committee and the Local Research Ethics Committees.
2.2. Assessment of psychotic experiences (PEs)
Psychotic experiences were assessed by the semi-structured
Psychosis-like Symptoms interview (PLIKSi) at a mean age of 12.9 years
(SD = 0.23). The interview instrument comprised 12 ‘core’questions de-
rived from the Diagnostic Interview Schedule for Children–IV (DISC–IV)
(Shaffer et al., 2000), and the Schedules for Clinical Assessment in Neu-
ropsychiatry version 2.0 (SCAN 2.0) (WHO, 1994). It included twelve
key symptoms covering the three main domains of positive psychotic
symptoms: hallucinations (visual and auditory); delusions (delusions
of being spied on, persecution, thoughts being read, reference, control,
grandiose ability, and other unspeciﬁed delusions); and bizarre symp-
toms (thought broadcasting, insertion and withdrawal). Interviewees
were asked about the presence of these symptoms and frequency of
symptoms. We used the observer based rating for the presence or ab-
sence of any psychotic experiences in the past six months as the main
outcome (i.e. a binary dependent variable). We also examined twelve
speciﬁc PEs individually as outcomes. The group with PEs was com-
pared with the rest of the cohort. We chose the binary deﬁnition of out-
come rather than a dimensional approach based on symptom frequency
in order to maximize power in multivariable regression analysis.
The interviews were carried out by 13 psychology graduates
who were trained by two experienced clinicians and SCAN trainers
(a child psychiatrist and a general adult psychiatrist) (Horwood et al.,
2008). The interviewers were required to reach 95% agreement whilst
scoring two ‘gold standard’ interview videotapes that were prepared
by the trainers. Monthly booster training sessions and workshops
were arranged to discuss scoring of complex cases and consolidate
training. All interviews were audiotaped for each interviewer until
they reached eight interviews containing several items rated ‘positive’
(i.e. PEs present). These tapes were independently rated by a second
Fig. 1. Timing of data collection and hypotheses for the study of atopic disorders, inﬂammatory markers and risk of psychotic experiences (PEs) in ALSPAC.
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interviewer. The average inter-rater reliability for PLIKS interviews
was good (kappa = 0.7) (Horwood et al., 2008). Parents were not
interviewed.
2.3. Assessment of atopic disorders
When ALSPAC participants were 10 years old their parents com-
pleted a postal questionnaire on various aspects of health and develop-
ment of the child. This included questions on atopic conditions. Parents
were askedwhether anytime in the past a doctor had stated that the child
suffered from asthma or eczema (original question: “Has a doctor ever
actually said that your study child has asthma or eczema?”). Based on re-
sponse to this question a single categorical exposure (or independent)
variable was created, which included four groups: no asthma or eczema
(reference group); only asthma; only eczema; both asthma and eczema.
2.4. Assays for inﬂammatory markers
IL-6, a proinﬂammatory cytokine, and CRP, an acute phase protein,
were measured in blood samples collected at age 9 years. Non-fasting
blood samples were taken using standard procedures, with samples
immediately spun and frozen at −80 °C. The measurements were
assayed in 2008 after a median of 7.5 years in storage with no previous
freeze–thaw cycles during this period (n = 5076). IL-6 was measured
by enzyme-linked immunosorbent assay (ELISA) (R&D systems,
Abingdon, UK). CRP was measured by automated particle-enhanced
immunoturbidimetric assay (Roche UK, Welwyn Garden City, UK). All
assay coefﬁcients of variation were b5% (Falaschetti et al., 2010).
Acute infection is likely to cause a transient increase in serum IL-6
and CRP levels. Since we were interested in inﬂammatory markers in
individuals with atopic disorders in healthy state, those who reported
to have an infection at the time of blood collection or in the preceding
week were excluded (n = 482). The information regarding infection
was gathered in the clinic during blood collection using a questionnaire.
IL-6, IL-1β and tumournecrosis factorα (TNF-α) are important cyto-
kines secreted by dendritic cells and macrophages following infection
(Janeway et al., 2001). These have a wide spectrum of biological effects
that help to coordinate the body's response to infection including in-
duction of acute phase proteins, raising body temperature (Janeway
et al., 2001). However, in other circumstances IL-6 also shows anti-
inﬂammatory activities (Scheller et al., 2011), which are consistent
with the pleiotropic nature of most cytokines (Janeway et al., 2001).
In ALSPAC, apart from IL-6 and CRP no other inﬂammatory markers
were assayed at age 9 years.
2.5. Assessment of covariates
Age at the time of assessment of PEs (inweeks) and gender were as-
sociated with atopic disorder (Table 1); these were included as poten-
tial confounders. We also included paternal social class and ethnicity,
common correlates of psychotic outcomes as potential confounders.
As per the UK Ofﬁce of National Statistics (ONS) classiﬁcation system
paternal social class was recorded in six categories (I, II, III non-
manual, III manual, IV, and V), in descending order, with professionals
and higher managerial workers representing social class I (Anon,
1980). In addition, ALSPAC recorded a separate category for fathers
working for the armed forces (0.3% of the entire cohort). However,
this category is likely to represent different ONS social groups, and we
did not have sufﬁcient information to reassign these individuals to the
original ONS categories. Therefore, the armed forces category was ex-
cluded from all analysis.
2.6. Statistical analysis
2.6.1. Atopic disorders and PEs
We used atopic disorders as the exposure/independent variable
(categorical) and PEs as the outcome/dependent variable (binary).
Multinomial logistic regressionwas used to calculate odds ratios for de-
veloping PEs in the following groups: asthma only; eczema only; both
asthma and eczema. Those with no asthma or eczema were used as
the reference group. Regression models were adjusted for age at the
time of assessment of PEs, gender, social class and ethnicity. We also
calculated the odds ratios for twelve speciﬁc PEs individually using the
same procedure.
2.6.2. Atopic disorders and inﬂammatory markers
The relationship between atopy and inﬂammatory markers was ex-
amined using linear regression. IL-6 and CRP values were not normally
distributed. Normality of distributions was achieved after natural loga-
rithmic transformation. Log transformed values of IL-6 and CRP were
used as the dependent variables. Regression models were adjusted for
age at the time of blood test, gender, body mass index (BMI), social
class and ethnicity, as these were associated with IL-6 (all p b 0.05).
2.6.3. Inﬂammatory markers and PEs
Median and interquartile range of the observed values of IL-6 and
CRP in those with PEs and the rest of the cohort have been presented.
Using log transformed values of IL-6 and CRP (standardized) as the
independent variable, we carried out binary logistic regression to calcu-
late the odds ratios for PEs. Thus, the odds ratios represent the increase
in the risk of PEs at age 13 years for each standard deviation increase
in serum levels of inﬂammatory markers at age 9 years.
2.6.4. Mediation analysis
Any mediating effects of IL-6 or CRP on the association between
atopy and PEs were examined using the following procedure (Judd
and Kenny, 1981; Baron and Kenny, 1986). First, separate regression
models assessed the associations between: (1) exposure (atopy) and
outcome (PEs); (2) exposure and mediator (IL-6); (3) mediator and
outcome controlling for exposure. If all of these associations were
statistically signiﬁcant, we proceeded to mediation analysis, whereby
exposure–outcome, exposure–mediator, mediator–outcome, all three
Table 1
Baseline characteristics of individuals with and without atopic disorders.
Groups/characteristics Asthma Eczema Both asthma and eczema No atopy p valuea
n (%) 1125 (14.4%) 994 (12.7%) 574 (7.3%) 5121 (65.5%)
Age at the time of assessment of PEs, mean (SD) in years 12.87 (0.24) 12.86 (0.20) 12.84 (0.19) 12.87 (0.21) 0.02
Male (%) 58.8 44.2 54.2 49.5 b0.001
British White (%) 98.3 97.7 98.1 98.4 0.75
Social class (%) 0.14
I 11.9 14.7 11.2 13.3
II 33.3 35.4 39.4 36.5
III non-manual 11.5 12.4 12.2 12.2
III manual 30.7 28.0 28.0 27.8
IV 10.4 7.2 7.7 7.7
V 2.2 2.3 1.5 2.5
a Chi-square test, except mean age, which is independent sample T-test.
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regression lines were ﬁtted simultaneously in a single model using
MPlus. It was expected that in the ﬁnal step, the exposure–outcome
relationship would be attenuated (partial mediation), or eliminated
(complete mediation). In case of partial mediation, the extent to
which the exposure–outcome estimate was attenuated after inclusion
of the mediator was also calculated. This procedure was repeated
using CRP as the potential mediator.
3. Results
3.1. Baseline characteristics
Data on atopic disorders stated by a doctor to be present in the child
any time since birth until age 10 years were available for 7814 children.
Onwhole, atopic disordersweremore common in boys than girls. Base-
line characteristics of individuals with and without atopic disorders
have been presented in Table 1.
3.2. Atopic disorders and the risk of psychotic experiences at age 13 years
Fig. 2 presents total percentage of individuals with psychotic experi-
ences (PEs) at age 13 years in different groups of atopic disorder at age
10 years.
Compared with those with no atopic disorder there was signiﬁcant
increase in risk of psychotic experiences at age 13 years among indi-
viduals with a history of atopic disorder (Table 2). Adjustment for
age, gender, social class and ethnicity had minimal inﬂuence on the
odds ratios. With regards to speciﬁc PEs, asthma and eczema were
associated with the risk of auditory hallucinations. The frequency of
individual PEs and their association with atopic disorders have been
presented in Table 3.
3.3. Association between atopy and inﬂammatory markers
Data on both atopy and inﬂammatory markers were available for
about 3850 individuals after excluding those with an infection at the
time of blood collection. Atopy was associated with increased serum
IL-6 (β = 0.051; SE = 0.014; p b 0.0001). The association was attenu-
ated after adjusting for age, BMI, gender, social class and ethnicity but still
remained statistically signiﬁcant (β = 0.036; SE = 0.015; p = 0.01).
Similar ﬁndings were observed for serum CRP (unadjusted β = 0.068;
SE = 0.019; p b 0.001; adjusted β = 0.039; SE = 0.019; p = 0.03).
3.4. Association between inﬂammatory markers and psychotic experiences
Data on inﬂammatory markers at age 9 years (after excluding those
with infection) and psychotic experiences at age 13 years were avail-
able for 3747 individuals. Out of these, 498 had PEs (13.29%). Medians
(interquartile range) of IL-6 for those with PEs and the rest of the
cohort were 0.78 (0.47–1.36), and 0.75 (0.47–1.33) pg/ml. Medians
(interquartile range) of CRP for those with PEs and the rest of the co-
hort were 0.22 (0.11–0.45), and 0.20 (0.11–0.47) mg/l.
Logistic regression showed that serum IL-6 and CRP levels were
not associated with the risk of psychotic experiences. For each stan-
dard deviation increase in IL-6 the odds ratio for PEs was 0.98 (95%
CI 0.90–1.08); p = 0.75. A similar result was observed for CRP; OR
1.03 (95% CI 0.93–1.14); p = 0.53.
3.5. Effect of inﬂammatory markers on the association between atopy
and PEs
We examined whether the association between atopy (the group
with both asthma and eczema) and PEs was mediated by serum IL-6.
Step by step analysis showed that: (1) exposure (atopy) was associated
with the outcome (PEs) (β = 0.368, SE = 0.14; p = 0.009); (2) expo-
sure (atopy) was associated with the mediator (IL-6) (β = 0.156,
SE = 0.05; p = 0.003); but (3) the mediator (IL-6) was not associated
with the outcome (PEs) after controlling for the exposure (atopy)
(β = 0.034, SE = 0.06; p = 0.61). Therefore, mediation analysis was
not attempted (where the exposure–outcome, exposure–mediator,
mediator–outcome all three regression lines would have been ﬁtted
simultaneously in a single model). However, in step three which in-
cluded both IL-6 and atopy as predictors of PEs, an attenuation of the
effect estimate between atopy and PEs was observed (β = 0.338,
SE = 0.18; p = 0.06), compared with that in step one. This equated
to only a 3% reduction of the atopy–PEs effect estimate by IL-6. Together,
these results indicated that in our sample IL-6 neither mediated nor
greatly confounded the association between atopy and PEs. Similar
results were observed for CRP.
4. Discussion
Ourﬁndings demonstrate that childhood atopic disorders are associ-
ated with the risk of developing psychotic experiences in adolescence.
Compared to children with no atopic disorder in the ﬁrst ten years
of life, an increased risk of PEs at age 13 years has been observed in all
groups with atopy (asthma, eczema, both). These associations are inde-
pendent of effects of age at the time of assessment of PEs, gender, social
class and ethnicity. To our knowledge, this is the ﬁrst population-based
longitudinal study of childhood atopic disorders and psychotic experi-
ences in adolescence. These results are in line with previous reports
of high comorbidity of asthma in adult schizophrenia (Chen et al.,
2009; Weber et al., 2009), and higher risk of developing schizophrenia
on follow-up among individuals with a history of atopic conditions
(asthma, atopic dermatitis, urticaria and allergic rhinitis) (Pedersen
et al., 2012).
An important methodological difference between our study and the
previous studies of atopic disorders and psychosis needs to be acknowl-
edged. The outcome of our studywas psychotic experiences in early ad-
olescence rather than diagnosis of schizophrenia. However, several lines
of evidence suggest that early-life psychotic experiences may provide aFig. 2. Psychotic experiences among individuals with atopic disorders.
Table 2
Atopic disorders and risk of psychotic experiences at age 13 years in ALSPAC cohort.
Exposure/independent
variable (atopy)a
Adjustment for
confounding
n Odds ratio (95% CI) for
the outcome/dependent
variable (PEs)
Eczema Unadjusted 5727 1.26 (1.00–1.58)
Adjustedb 4923 1.33 (1.04–1.69)
Asthma Unadjusted 5727 1.35 (1.09–1.86)
Adjusted 4923 1.37 (1.08–1.74)
Both asthma and eczema Unadjusted 5727 1.45 (1.10–1.90)
Adjusted 4923 1.44 (1.07–1.95)
a The group with no atopic disorders (i.e. no asthma or eczema) was used as reference
(odds ratio = 1).
b Adjusted for age at the time of assessment of PEs, gender, social class and ethnicity.
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valid paradigm for studying the development of adult psychotic disor-
ders (Kelleher and Cannon, 2011; Murray and Jones, 2012). First, pro-
spective birth cohort studies suggest higher risk of psychotic disorders
in adult life among individuals reporting psychotic symptoms in child-
hood (Poulton et al., 2000; Zammit et al., 2013). Second, childhood
psychotic symptoms are associated with a number of risk factors for
schizophrenia, such as prenatalmaternal infection andobstetric compli-
cations (Zammit et al., 2009), low birth weight (Thomas et al., 2009),
and poorer childhood IQ (Horwood et al., 2008). Increased prevalence
of antibodies to Epstein Barr Virus has been reported in adolescents
reporting psychotic experiences (Wang et al., 2011) and in adult schizo-
phrenia (Delisi et al., 1986). A recent study from theALSPAC birth cohort
has reported increased risk of psychotic experiences in adolescence for
autistic traits in early childhood (Bevan Jones et al., 2012). Together,
these ﬁndings indicate that childhood psychotic experiences may have
a developmental component to their origin. Third, population-based
studies suggest psychotic symptoms in the general population and
that observed in psychotic disorders may exist in a continuum (van Os
et al., 2009). Finally, neurophysiological studies suggest common under-
lyingmechanisms for psychotic symptoms seen in healthypeople and in
schizophrenia (Howes et al., 2013).
One explanation for the association between atopy and PEs could be
the effect of medication. Individuals with asthma or treatment resistant
eczema are sometimes prescribed oral steroids, which are also associ-
ated with the risk of psychosis. We did not have the data on steroid
prescriptions. Thus the possibility of steroid medication as a mediator
of the association between atopy and PEs cannot be ruled out.
Limitations of this study include the use of parent reported data
rather than conﬁrmatory tests for asthma or eczema. However, the
questionnaire asked whether these conditions had been diagnosed by
a doctor. Using a similar question (Have you ever had asthma?) the
prevalence of asthma has been reported to be about 10% in 6–7 year
old children in the Western Europe including UK (Lai et al., 2009), and
about 20% in 12–14 year old children in the UK (Kaur et al., 1998).
These are comparable to the prevalence of parent-reported asthma in
our sample (14.4% at age 10 years). Both atopy and PEs were assessed
prospectively; thus, eliminating any chance of recall bias.
Degradation of inﬂammatory markers over time is possible. How-
ever, serum samples were frozen at −80 °C, which is recommended
as the optimum temperature for storage of these samples for cytokine
assays at a later stage (Holland et al., 2003; de Jager et al., 2009). There
was no evidence of prior freeze–thaw cycles. Cytokine levels in blood
samples collected at a non-fasting state could be affected by diurnal ef-
fect (de Jager et al., 2009). However, the use of non-fasting samples
would increase measurement error likely to be random in relation to
outcome. We acknowledge that inﬂammatory markers were measured
at age 9 years, and data on atopy were collected slightly later at age
10 years (Fig. 1). However, this is justiﬁed as the questionnaire asked
about the diagnosis of atopy anytime in the past since birth, and atopy
is considered as a long-term attribute in many individuals (Boulay and
Boulet, 2003). The approach is also consistent with our hypothesis and
the direction of association, i.e. atopy leads to increased IL-6/CRP.
To our knowledge, this is the ﬁrst longitudinal study of childhood
inﬂammatory markers and subsequent risk of psychotic outcomes.
Meta-analyses have reported increased levels of inﬂammatory markers
including IL-6 and CRP in schizophrenia (Miller et al., 2011, 2013). How-
ever, due to their cross sectional design these studies cannot establish
whether increased inﬂammatory markers is a cause or consequence of
the illness. We found no association between IL-6/CRP at age 9 years
and risk of PEs at age 13 years. This could be due to a number of reasons.
Measurement error as a result of non-fasting serum samples would
contribute to the null ﬁnding. A previous meta-analysis suggests that
IL-6 may be a state marker of acute psychosis (Miller et al., 2011).
Since IL-6 is the primary inducer of CRP, the latter might also be a
state marker. Thus, measurement of IL-6 and CRP several years before
the assessment of PEs might explain whywe did not observe an associ-
ation between inﬂammatory markers and PEs. The same meta-analysis
reported that other cytokines, including sIL-2R, IL-12, and TNF-α,
appeared to be trait markers for schizophrenia (Miller et al., 2011).
However, these cytokines were not included when the serum samples
were analysed a few years ago in ALSPAC. In the future, studies should
include a more comprehensive panel of inﬂammatory markers in-
cluding cytokines andwhite blood cellsmeasured over a period of time.
Effect of inﬂammatory cytokines on the developing brain has been
proposed as a possible mechanism underlying the association between
schizophrenia and early life infection. Birth cohort studies suggest that
inﬂammatory cytokines (TNF-α) or chemokines (IL-8) may mediate
the risk of schizophrenia in adult offspring associated with prenatal
maternal infection (Buka et al., 2001b; Brown et al., 2004b). A possible
role of inﬂammation in the pathogenesis of psychosis is also supported
by animal studies. Simulated viral or bacterial infection or direct injec-
tion with the inﬂammatory cytokine IL-6 in pregnant mice has been
reported to produce intermediate phenotypes related to schizophrenia
in the adult offspring (Meyer and Feldon, 2010). Some of these pheno-
types, such as deﬁcits in sensory gating and abnormal latent inhibition
are reversible by the antipsychotic clozapine (Smith et al., 2007). How-
ever, in our sample there was no indication that inﬂammatory markers
explained the association between atopy and PEs. This could be related
to the outcome studied. Adolescent participants with PEs in our sample
are almost certainly a heterogeneous group. In many cases these symp-
toms are likely to be part of normal development, whilst in some they
may be more pathological (De Loore et al., 2011; Rubio et al., 2012).
Thus, any underlying biological effect (such as mediation by inﬂamma-
tory markers) may have become diluted. Nevertheless, we found that
atopic disorders were associated with higher levels of inﬂammatory
markers and increased risk of PEs. Follow-up of these individuals will
be useful to explore further the effect of atopy and inﬂammation on
different developmental trajectories of early-life PEs.
Table 3
Associations between atopic disorders and speciﬁc psychotic experiences in ALSPAC cohort.
Psychotic experiences (PEs) Sample (% of PEs) Odds ratio (95% CI) for PEs in groups of atopic disorder
Asthma Eczema Both
Auditory hallucinations 5722 (6.8) 1.60 (1.21–1.99) 1.49 (1.11–1.99) 1.35 (0.93–1.97)
Visual hallucinations 5728 (2.4) 1.20 (0.74–1.96) 1.39 (0.87–2.22) 1.16 (0.61–2.20)
Delusions of being spied on 5723 (2.7) 1.05 (0.65–1.68) 1.00 (0.61–1.63) 1.33 (0.76–2.31)
Delusions of persecution 5723 (0.2) 0.46 (0.06–3.61) 0.48 (0.06–3.97) 0.85 (0.11–6.65)
Delusions of thought being read 5729 (0.6) 1.01 (0.38–2.66) 0.84 (0.29–2.44) 1.11 (0.33–3.72)
Delusions of reference 5729 (0.7) 0.85 (0.33–2.23) 0.72 (0.25–2.05) 0.94 (0.28–3.13)
Delusions of control 5728 (0.6) 1.01 (0.38–2.65) 0.84 (0.30–2.44) 1.86 (0.70–4.92)
Delusions of grandiose ability 5729 (1.1) 0.51 (0.20–1.30) 0.75 (0.34–1.67) 1.33 (0.60–2.97)
Other delusions 5727 (0.4) 0.38 (0.05–2.96) 1.21 (0.34–4.31) 3.57 (1.25–10.20)
Thought broadcasting 5725 (1.3) 1.51 (0.80–2.84) 1.84 (1.01–3.34) 1.50 (0.66–3.36)
Thought insertion 5729 (1.3) 1.21 (0.64–2.30) 0.95 (0.46–1.94) 0.92 (0.36–2.34)
Thought withdrawal 5727 (0.3) 0.61 (0.14–2.70) 0.64 (0.18–2.83) 0.56 (0.07–4.31)
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Possible explanations for the observed association between atopy
and psychotic experiences include an overlap of genetic risk between
atopy and psychosis. For example, shared genetic susceptibility for
schizophrenia and asthma has been proposed (Harrison and Law,
2006;Moffatt et al., 2007; Akhabir and Sandford, 2011). Recent genome
wide association studies have reported signiﬁcant associations between
schizophrenia and several markers spanning the major histocompati-
bility complex region on chromosome 6p21.3–22.1. This is consistent
with an immune component to schizophrenia risk (Shi et al., 2009;
Stefansson et al., 2009). Thus, it is possible that atopic conditions, in
the presence of pre-existing genetic liability, can lead to a distinct or
pathological immune response. In turn, this may lead to CNS alterations
making these individuals susceptible to developing psychotic illness in
adult life. In the future, prospective epidemiological studieswith genetic
and immunological data as well as detailed phenotypic characterisation
during childhood and adult life are required to test this hypothesis.
Animal models will be useful to identify speciﬁc mechanisms under-
lying behavioural and cognitive phenotypes relevant to schizophrenia
involving genes and immunity.
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